B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL (Q81306380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

E Fronkova

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

K Muzikova

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

E Mejstrikova

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

M Kovac

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

R Formankova

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

P Sedlacek

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

O Hrusak

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

J Stary

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

J Trka

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

19 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

187-196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18490915%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bmt.2008.122

7 January 2020

exact match

0 references

cites work

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leu

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Childhood and adolescent lymphoid and myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Minimal residula disease status as a predictor of relapse after allogenic bone marrow transplantation for children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Donor leukocyte infusions in acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Relapse of Philadelphia chromosome positive acute lymphoblastic leukaemia after marrow transplantation: sustained molecular remission after early and dose-escalating infusion of donor leucocytes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Allogeneic transplantation for childhood ALL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

New therapeutic strategies for the treatment of acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

The human immunoglobulin VH repertoire

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Human Ig heavy chain CDR3 regions in adult bone marrow pre-B cells display an adult phenotype of diversity: evidence for structural selection of DH amino acid sequences.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021

Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.122

7 January 2021